Pramipexole dihydrochloride (cas 104632-25-9) loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity

Add time:08/18/2019    Source:sciencedirect.com

In the current study, Pramipexole dihydrochloride (cas 104632-25-9) loaded chitosan nanoparticles (P-CNs) were prepared for Parkinson’s disease via nose to brain pathway by ionic gelation method. Optimized P-CNs with chitosan and sodium tripolyphosphate (6:1 v/v) exhibited particle size and entrapment efficiency of 292.5 nm ± 8.80 and 91.25% ± 0.95 respectively and its diffusion across the artificial membrane and goat nasal mucosa was found to be 93.32% ± 2.56 and 83.03% ± 3.48 correspondingly after 24 h. Transmission electron microscopy displayed the spherical nature of the P-CNs particles and rough surface morphology was observed in scanning electron microphotographs. In pharmacodynamic studies, the comparative results of behavioral testing revealed improved score of photoactometer and reduced motor deficit in the form of catalepsy in P-CN treatment group as compare to its nasal solution or oral marketed tablets. Similarly, P-CNs enhanced antioxidant status in the form of increased superoxide dismutase and catalase activities, along with increased dopamine level in the brain significantly. Therefore, it can be concluded that intranasal delivery of Pramipexole loaded chitosan nanoparticles exhibited essential in vitro characteristics and superior in vivo activity than other formulations for brain targeted delivery in Parkinson disease.

We also recommend Trading Suppliers and Manufacturers of Pramipexole dihydrochloride (cas 104632-25-9). Pls Click Website Link as below: cas 104632-25-9 suppliers

Prev:Improved biooxidation of Benzyl alcohols catalyzed by the flavoprotein (5-Hydroxymethyl)furfural oxidase in organic solvents
Next:Validated chiral liquid chromatographic method for the enantiomeric separation of Pramipexole dihydrochloride (cas 104632-25-9) monohydrate)